Johnson Pharmacare (532154) Q1 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 24/25 earnings summary
13 Jun, 2025Executive summary
Board approved unaudited financial results for the quarter ended June 30, 2024 at its August 1, 2024 meeting.
Financial highlights
Total income for Q1 FY25 was ₹3.99 lakhs, down from ₹18.78 lakhs in Q4 FY24 and ₹19.62 lakhs in Q1 FY24.
Net loss for Q1 FY25 stood at ₹3.99 lakhs, compared to a net loss of ₹0.20 lakhs in Q4 FY24 and ₹18.78 lakhs in Q1 FY24.
Earnings per share (basic and diluted) remained at ₹(0.00) for the quarter.
Key financial ratios and metrics
Paid-up equity share capital was ₹5,500 lakhs as of June 30, 2024.
Other equity reported at ₹175.30 lakhs as of March 31, 2024.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Johnson Pharmacare
- New auditor and independent director appointed, with all regulatory confirmations in place.532154
Q3 25/2613 Feb 2026 - No revenue and continued net losses reported for the quarter ended September 30, 2025.532154Q2 25/2618 Nov 2025
- Net loss narrowed for Q2 and H1 FY25, with negligible revenue and stable equity.532154Q2 24/2530 Oct 2025
- Profit recovery and portfolio upgrades contrast with a widened net loss in another period.532154Q1 25/2630 Jul 2025
- Net loss widened to Rs. 58.38 lakhs in FY25, driven by a SEBI penalty and no revenue.532154Q4 24/256 Jun 2025
- Q3 FY25 saw flat revenue and a net loss, with auditors raising no concerns.532154Q3 24/256 Jun 2025